• Increase font size
  • Default font size
  • Decrease font size

Subscriber Only Content

More News

Breaking News

More News

RSS Subscription

Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On "Striking" Clinical Trial Data

Below is a look at some of the headlines for companies that made news in the healthcare sector on February 3, 2012.
Read more...
 

Medgenics has Key to Protein Therapy Market

FDA CalendarMedgenics (NASDAQ: MDGN) has what I believe to be the most disruptive biotechnology of the last 20 years.  This company is poised to own the 90 billion plus protein therapy market. We are talking about an enormous indication.  Nomura (the big investment bank) Calls this one of the top 10 biotech companies to watch over the next 5 years.
Read more...
 

Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR

Below is a look at some of the headlines for companies that made news in the healthcare sector on February 2, 2012.
Read more...
 

OncoSec's President and CEO explains his firm's ambitious list of milestones for 2012

CEO OncosecDuring the past few sessions, we've been watching shares of OncoSec Medical Inc. (OTCBB: ONCS) rising on heavy trading so we reached out to Punit Dhillon, President and CEO for an interview to find out why investors are starting to take positions in the company after a slow but steady sell-off in the market.
Read more...
 

Pfizer Issues Statement On Voluntary Recall; Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial

Below is a look at some of the headlines for companies that made news in the healthcare sector on February 1, 2012.
Read more...
 

Biotech speculators continue to buy into positive attention

FDA CalendarShares of PROLOR Biotech, Inc. (AMEX:PBTH) have been on the move since we told readers about the company in January and jumped another 2.81% on Tuesday.
Read more...
 

FDA Approves Kalydeco to Treat Rare Form of CF; Glaxo, Lilly, Pfizer Said to Be Interested in Turkey’s MN Pharma

Below is a look at some of the headlines for companies that made news in the healthcare sector on January 31, 2012.
Read more...
 

ImmunoCellular Therapeutics shares rocket on heavy volume

FDA CalendarTrading volume for shares of ImmunoCellular Therapeutics (OTCBB:IMUC) has been on the rise during the past few sessions.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 276
about 8 hours ago Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On "Striking" Clinical Trial Data: Below i... http://t.co/IbLYNqgb
about 16 hours ago Shares of $IDIX drop slightly after compelling new data from rival Gilead ($GILD) puts prospects for IDIX's hepatitis C drug in question.
about 1 day ago Medgenics has Key to Protein Therapy Market: Medgenics (NASDAQ: MDGN) has what I believe to be the most disrupti... http://t.co/c3IBIWYR
about 1 day ago Stocks Vacillate To Mixed Finish; Some Leaders Rally http://t.co/dtOQTRgh
about 1 day ago Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR: Belo... http://t.co/a7IlIvbS
about 1 day ago Athersys $ATHX gets grant to study traumatic brain injury http://t.co/mnZTsxXx
about 1 day ago Watching: San Antonio patients help test new 'spray-on skin' for burns http://t.co/fzKA9B23
about 1 day ago OncoSec's President and CEO explains his firm's ambitious list of milestones for 2012: During the past few sessi... http://t.co/fKOMc1TM

navigation

Free Phone Trade Alerts